CG Oncology (CGON) Non Operating Income (2023 - 2026)
CG Oncology's (CGON) quarterly Non Operating Income came in at $6.2 million in Q1 2026, down 20.19% YoY from $7.8 million in Q1 2025, and down 16.29% on a QoQ basis from $7.4 million in Q4 2025.
CG Oncology (CGON) Non Operating Income (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Non Operating Income data on file, last reported at $6.2 million in Q1 2026.
- Quarterly Non Operating Income fell 20.19% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 million (down 2.18% YoY) and the FY2025 annual result came in at $29.8 million, up 11.84% from the prior year.
- Non Operating Income declined to $6.2 million in Q1 2026, from $7.4 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $7.9 million in Q3 2024 to a low of $713000.0 in Q2 2023.
- A 4-year average of $5.3 million and a median of $6.3 million in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income jumped 874.89% — and 2026, when it decreased 20.19%.
- Tracing CGON's Non Operating Income over 4 years: stood at $2.8 million in 2023, then jumped by 123.25% to $6.3 million in 2024, then grew by 18.24% to $7.4 million in 2025, then slipped by 16.29% to $6.2 million in 2026.
- The last three Non Operating Income figures came in at $6.2 million (Q1 2026), $7.4 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 7.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.35 Mn |
| Mar 31, 2026 | 6.19 Mn |
| Dec 31, 2025 | 7.39 Mn |
| Sep 30, 2025 | 7.32 Mn |
| Jun 30, 2025 | 7.32 Mn |
| Mar 31, 2025 | 7.75 Mn |
| Dec 31, 2024 | 6.25 Mn |
| Sep 30, 2024 | 7.89 Mn |
| Jun 30, 2024 | 6.95 Mn |
| Mar 31, 2024 | 5.54 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Sep 30, 2023 | 2.28 Mn |
| Jun 30, 2023 | 713,000.00 |
| Mar 31, 2023 | 1.05 Mn |